PI314101
IFN beta Polyclonal Antibody, Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PI314101-Each-of-1 | In Stock | ₹ 44,722.50 |
PI314101 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 44,722.50
GST (18%): ₹ 8,050.05
Total Price: ₹ 52,772.55
Antigen
IFN beta
Classification
Polyclonal
Conjugate
Unconjugated
Gene
Ifnb1
Gene Alias
Fibroblast interferon; Ifb; IFF; IFN b; IFN β; IFNB; Ifnb1; IFNbeta; IFN-beta; IFNβ; Interferon b; Interferon beta; interferon beta 1; interferon beta 1, fibroblast; interferon beta protein; interferon, beta 1; interferon, beta 1, fibroblast; interferon-beta; RP11-113D19.1
Host Species
Rabbit
Quantity
2 x10^4 units
Primary or Secondary
Primary
Target Species
Human
Product Type
Antibody
Isotype
IgG
Applications
Neutralization
Concentration
Conc. Not Determined
Formulation
whole serum diluted in PBS with no preservative
Gene Accession No.
P01574
Gene Symbols
Ifnb1
Immunogen
Recombinant human interferon beta
Regulatory Status
RUO
Gene ID (Entrez)
3456
Content And Storage
-20° C, Avoid Freeze/Thaw Cycles
Form
Liquid
Related Products
Description
- Specificity: Neutralizes human interferon beta
- Activity: 2.8x10^5 NU/mL
- Interferon was titrated with the use of the cytopathic effect inhibition assay using A549 cells with EMCV, where 1 unit/mL of interferon was necessary to produce an endpoint of 50%
- One neutralization unit is defined as the amount of serum required to neutralize one unit of human IFN beta to an endpoint of 50%
- Store at -20°C for short-term use (less than 6 months)
- For long-term storage, aliquot and store at -70°C or below for retention of full activity
- Refreezing should be done on dry ice or in a dry ice/alcohol bath
- Further dilution of the product should be in buffers containing protein such as 0.1% BSA
- Packaged by and distributed for PBL Assay Science
- Type I Interferons (IFN-alpha/beta) are produced primarily in response to viral infection by Natural IFN-producing cells (IPCs) as part of the host immune response
- IFNs can also inhibit the development of tumors
- IFN-beta binding results in the activation of the tyrosine kinases Jak1 and Tyk2, phosphorylation of members of the STAT family of transcription factors, and the transcription and expression of the immune response genes
- More recently, several members of the toll-like receptor (TLR) family were found to stimulate the production IFN-beta
- IFN-beta is currently used clinically for treatment of tumors, infections and multiple sclerosis.